Market Overview:
The global anti-depressant market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of depression, rising awareness about mental health disorders, and growing demand for novel anti-depressants. The global anti-depressant market is segmented on the basis of type into tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and serotonin antagonists/reuptake inhibitors. The SSRI segment is expected to account for the largest share of the global anti-depressant market in 2018. This segment is projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030.
Product Definition:
An antidepressant is a psychiatric medication used to alleviate mood disorders, such as major depressive disorder and anxiety disorders.
Tricyclic Antidepressants:
Tricyclic antidepressants (TCAs) are a class of medication primarily used for the treatment of depression. They are also used as an anti-depressant and to relieve symptoms of withdrawal from some drugs, such as opioids and benzodiazepines. TCA is a type of selective serotonin reuptake inhibitor (SSRI). SSRIs are commonly prescribed for depression but they can have side effects such as suicidal thoughts or other mental health problems.
Selective Serotonin Reuptake Inhibitors:
SSRI's are used to treat depression and other associated disorders by decreasing the amount of serotonin (a chemical in the brain) that is reabsorbed by nerve cells. SSRIs block some of the serotonin receptors so that more gets into the synapse (space between neurons), where it can bind with opiate receptors and produce its usual effects.
Application Insights:
Major depressive disorder (MDD) held the largest share of 32.1% in 2017. MDD is a mental illness characterized by low mood, anxiety and stress for a long period of time that affects a person's daily life and ability to function normally. According to the World Health Organization (WHO), around 40 million people suffered from MDD in 2013 across the globe, with women suffering from depression twice as much as men. The U.S., India, China and Russia were among top five countries where most number of patients suffered from major depression in 2013 owing to high prevalence rates combined with accessibility of treatments through online as well as offline channels which are mostly available at affordable prices compared to private practices or hospitals.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, availability of improved healthcare facilities and high consumer disposable income are some factors responsible for its largest share. Moreover, rising awareness about mental health is expected to fuel the growth over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast period owing to improving economic conditions and growing consumer disposable income levels in emerging countries such as China and India. Furthermore, increasing investments by major pharmaceutical companies for launching new products coupled with rising prevalence rates for depressive disorders are other factors driving this regional market forward during the estimated time span.
Growth Factors:
- Increasing awareness about mental health and its treatment options
- Growing prevalence of depression and other mental disorders
- Rising demand for better and faster-acting antidepressants
- Availability of government funding for research on new antidepressant drugs
- Emergence of novel antidepressant therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-Depressant Market Research Report
By Type
Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist, Reuptake Inhibitors, Others
By Application
Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others
By Companies
Alkermes, Allergan, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Merck, Pfizer, Teva Pharmaceutical Industries, Takeda Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Anti-Depressant Market Report Segments:
The global Anti-Depressant market is segmented on the basis of:
Types
Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist, Reuptake Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alkermes
- Allergan
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Lundbeck
- Merck
- Pfizer
- Teva Pharmaceutical Industries
- Takeda Pharmaceutical
Highlights of The Anti-Depressant Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tricyclic Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Serotonin-Norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors
- Serotonin Antagonist
- Reuptake Inhibitors
- Others
- By Application:
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Depressant Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
An antidepressant is a medication that helps to improve mood and reduce symptoms of depression.
Some of the major companies in the anti-depressant market are Alkermes, Allergan, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Merck, Pfizer, Teva Pharmaceutical Industries, Takeda Pharmaceutical.
The anti-depressant market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Depressant Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-Depressant Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-Depressant Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-Depressant Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-Depressant Market Size & Forecast, 2020-2028
4.5.1 Anti-Depressant Market Size and Y-o-Y Growth
4.5.2 Anti-Depressant Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tricyclic Antidepressants
5.2.2 Selective Serotonin Reuptake Inhibitors
5.2.3 Serotonin-Norepinephrine Reuptake Inhibitors
5.2.4 Monoamine Oxidase Inhibitors
5.2.5 Serotonin Antagonist
5.2.6 Reuptake Inhibitors
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Major Depressive Disorder
6.2.2 Obsessive-Compulsive Disorder
6.2.3 Generalized Anxiety Disorder
6.2.4 Panic Disorder
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-Depressant Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Depressant Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tricyclic Antidepressants
9.6.2 Selective Serotonin Reuptake Inhibitors
9.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
9.6.4 Monoamine Oxidase Inhibitors
9.6.5 Serotonin Antagonist
9.6.6 Reuptake Inhibitors
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Major Depressive Disorder
9.10.2 Obsessive-Compulsive Disorder
9.10.3 Generalized Anxiety Disorder
9.10.4 Panic Disorder
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tricyclic Antidepressants
10.6.2 Selective Serotonin Reuptake Inhibitors
10.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
10.6.4 Monoamine Oxidase Inhibitors
10.6.5 Serotonin Antagonist
10.6.6 Reuptake Inhibitors
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Major Depressive Disorder
10.10.2 Obsessive-Compulsive Disorder
10.10.3 Generalized Anxiety Disorder
10.10.4 Panic Disorder
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tricyclic Antidepressants
11.6.2 Selective Serotonin Reuptake Inhibitors
11.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
11.6.4 Monoamine Oxidase Inhibitors
11.6.5 Serotonin Antagonist
11.6.6 Reuptake Inhibitors
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Major Depressive Disorder
11.10.2 Obsessive-Compulsive Disorder
11.10.3 Generalized Anxiety Disorder
11.10.4 Panic Disorder
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tricyclic Antidepressants
12.6.2 Selective Serotonin Reuptake Inhibitors
12.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
12.6.4 Monoamine Oxidase Inhibitors
12.6.5 Serotonin Antagonist
12.6.6 Reuptake Inhibitors
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Major Depressive Disorder
12.10.2 Obsessive-Compulsive Disorder
12.10.3 Generalized Anxiety Disorder
12.10.4 Panic Disorder
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tricyclic Antidepressants
13.6.2 Selective Serotonin Reuptake Inhibitors
13.6.3 Serotonin-Norepinephrine Reuptake Inhibitors
13.6.4 Monoamine Oxidase Inhibitors
13.6.5 Serotonin Antagonist
13.6.6 Reuptake Inhibitors
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Major Depressive Disorder
13.10.2 Obsessive-Compulsive Disorder
13.10.3 Generalized Anxiety Disorder
13.10.4 Panic Disorder
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-Depressant Market: Competitive Dashboard
14.2 Global Anti-Depressant Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alkermes
14.3.2 Allergan
14.3.3 Bristol-Myers Squibb
14.3.4 Eli Lilly and Company
14.3.5 GlaxoSmithKline
14.3.6 Lundbeck
14.3.7 Merck
14.3.8 Pfizer
14.3.9 Teva Pharmaceutical Industries
14.3.10 Takeda Pharmaceutical
